Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

HEALTH PROFESSIONAL · SOURCE READING

Tremelimumab

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC (First-Line Therapy) / Immune checkpoint inhibitors with or without chemotherapy

Tremelimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). It is an immune checkpoint blocker.

Continue within this section

Durvalumab plus tremelimumab plus chemotherapy →

Preserved source evidence · Not medical advice